Generic Medicine Info
Special Precautions
Ensure that chromaturia does not mask colour changes due to other reasons (e.g. renal or blood disorders). Renal and hepatic impairment. Pregnancy and lactation. Monitoring Parameters Monitor patient regularly according to local clinical guidelines.
Adverse Reactions
Significant: Chromaturia (reddish-brown urine discolouration). General disorders and administration site conditions: Malaise. Gastrointestinal disorders: Diarrhoea, nausea, vomiting, dyspepsia. Musculoskeletal and connective tissue disorders: Back pain, pain in the extremity. Nervous system disorders: Headache, dizziness. Respiratory, thoracic and mediastinal disorders: Nasopharyngitis, cough. Skin and subcutaneous tissue disorders: Rash, pruritus.
Drug Interactions
Repeated administration may increase the serum concentrations of CYP3A4 substrates (e.g. midazolam, terfenadine, cisapride, ciclosporin, fentanyl, pimozide, quinidine, tacrolimus, ergotamine). May inhibit P-glycoprotein which may increase the exposure of dabigatran etexilate, digoxin, or aliskiren.
ATC Classification
N06BX13 - idebenone ; Belongs to the class of other psychostimulants and nootropics.
Disclaimer: This information is independently developed by CIMS based on idebenone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in